Perampanel in the management of partial-onset seizures: a review of safety, efficacy, and patient acceptability

Patient Preference and Adherence
Andreas Schulze-Bonhage, Mandy Hintz

Abstract

Perampanel (PER) is a novel antiepileptic drug recently introduced for the adjunctive treatment in epilepsy patients aged 12 years or older with partial-onset seizures with or without secondary generalization in the US and Europe. Its antiepileptic action is based on noncompetitive inhibition of postsynaptic AMPA receptors, decreasing excitatory synaptic transmission. Evaluation of efficacy in three placebo-controlled randomized Phase III studies showed that add-on therapy of PER decreased seizure frequencies significantly compared to placebo at daily doses between 4 mg/day and 12 mg/day. PER's long half-life of 105 hours allows for once-daily dosing that is favorable for patient compliance with intake. Long-term extension studies showed a 62.5%-69.6% adherence of patients after 1 year of treatment, comparing favorably with other second-generation antiepileptic drugs. Whereas these trials demonstrated an overall favorable tolerability profile of PER, nonspecific central nervous system adverse effects like somnolence, dizziness, headache, and fatigue may occur. In addition, neuropsychiatric disturbances ranging from irritability to suicidality were reported in several case reports; both placebo-controlled and prospective long-te...Continue Reading

Citations

Jun 9, 2016·Der Nervenarzt·M HintzA Schulze-Bonhage
Dec 24, 2018·Expert Opinion on Drug Metabolism & Toxicology·Stefano de BiaseMariarosaria Valente
Jun 3, 2016·Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research·Leslie A RudzinskiIoannis Karakis
Feb 26, 2016·CNS Drugs·Eman BahraniJoseph S Kass

❮ Previous
Next ❯

Methods Mentioned

BETA
lavage
X-ray
biopsy
contraception

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.

Related Papers

Pharmacological Research : the Official Journal of the Italian Pharmacological Society
V FrancoE Grillo
© 2021 Meta ULC. All rights reserved